RGNX übertreffen die 16 der letzten 40Schätzungen.
40%
Nächster Bericht
Datum des nächsten Berichts
11. März 2026
Estimate forQ4 25(Revenue/ EPS)
$50.48M
/
-$0.85
Implizierte Änderung vonQ3 25(Revenue/ EPS)
+69.79%
/
-29.17%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
+137.97%
/
-15.84%
REGENXBIO Inc. earnings per share and revenue
On 06. Nov. 2025, RGNX reported earnings of -1.20 USD per share (EPS) for Q3 25, beating the estimate of -1.33 USD, resulting in a 9.88% surprise. Revenue reached 29.73 million, compared to an expected 24.61 million, with a 20.83% difference. The market reacted with a -3.79% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 14 analysts forecast an EPS of -0.85 USD, with revenue projected to reach 50.48 million USD, implying an decrease of -29.17% EPS, and increase of 69.79% in Revenue from the last quarter.
FAQ
What were REGENXBIO Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, REGENXBIO Inc. reported EPS of -$1.20, beating estimates by 9.88%, and revenue of $29.73M, 20.83% above expectations.
How did the market react to REGENXBIO Inc.'s Q3 2025 earnings?
The stock price moved down -3.79%, changed from $11.61 before the earnings release to $11.17 the day after.
When is REGENXBIO Inc. expected to report next?
The next earning report is scheduled for 11. März 2026.
What are the forecasts for REGENXBIO Inc.'s next earnings report?
Based on 14
analysts, REGENXBIO Inc. is expected to report EPS of -$0.85 and revenue of $50.48M for Q4 2025.